NCT03458260 2026-03-10
Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma
The Lymphoma Academic Research Organisation
Phase 2 Completed
Clinical Trials
9 trialsNCT01632436 2023-10-02
Hepatic
CTI BioPharma
Phase 1 Withdrawn
NCT01321541 2021-11-19
PIX-R
CTI BioPharma
Phase 3 Completed
NCT00577161 2020-10-05
Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHL
CTI BioPharma
Phase 3 Withdrawn
NCT01491841 2020-03-04
BRP
Duke University
Phase 1 Completed
NCT00088530 2020-02-05
BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)
CTI BioPharma
Phase 3 Completed
NCT02800889 2020-01-29
Dose-Escalation Study of Pixantrone Monotherapy in Pediatric Patients With Relapsed or Refractory Cancer
CTI BioPharma
Phase 1 Withdrawn
NCT00060671 2015-01-19
Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's Lymphoma
CTI BioPharma
Phase 3 Terminated
NCT00060684 2015-01-19
Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma
CTI BioPharma
Phase 1 Completed